LUMINEX CORPORATION (NASDAQ:LMNX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Number of Shares

Voted Against

Broker Non-Votes

ME Staff 8-k

8 years ago

LUMINEX CORPORATION (NASDAQ:LMNX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

The Board of Directors of Luminex Corporation (the “Company”)
previously approved, subject to stockholder approval, the Amended
and Restated Luminex Corporation Employee Stock Purchase Plan (the
Employee Stock Purchase Plan). According to the results from the
Companys 2017 Annual Meeting of Stockholders (the “Annual
Meeting”) held on May 18, 2017, the Companys stockholders approved
the Employee Stock Purchase Plan. A detailed summary of the
material terms of the Employee Stock Purchase Plan appears on pages
13 – 17 of the Companys Definitive Proxy Statement on Schedule 14A,
which was filed with the Securities and Exchange Commission (the
SEC) on April 3, 2017 (the Proxy Statement). The foregoing
description of the Employee Stock Purchase Plan is qualified in its
entirety by reference to the full text of the Employee Stock
Purchase Plan, which is filed as Annex A to the Proxy Statement and
incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, which was held at the Company’s office in
Austin, Texas, a total of 40,670,466 shares of the Company’s
common stock, out of a total of 43,938,065 shares of common stock
outstanding and entitled to vote, were present in person or
represented by proxies. The following proposals were voted on at
the Annual Meeting:

Proposal 1: Election of Class II Directors

The stockholders approved the Companys proposal for the election of
two persons nominated by the Board of Directors for three-year
terms as Class II directors, as set forth below:



	Number of Shares
	Voted For	Withheld	Abstained	Broker Non-Votes
Stephen L, Eck, M.D., Ph.D.	32,869,713	64,454	1,052,370	6,683,929
Jim D. Kever	33,626,302	69,775	290,460	6,683,929

Proposal 2: Advisory Vote to Approve Named Executive Officer
Compensation

The stockholders cast an advisory vote regarding the compensation
of the Company’s named executive officers, as described in the
Compensation Discussion and Analysis, executive compensation tables
and accompanying narrative disclosures in the Company’s Proxy
Statement for the Annual Meeting, as set forth below:

Proposal 3: Advisory Vote on the Frequency of Future Advisory
Votes on Named Executive Officer Compensation

The stockholders cast an advisory vote regarding the frequency of
the advisory votes on the compensation of the Company’s named
executive officers (once every year, every two years or every three
years), as set forth below:



Number of Shares
One Year	Two Years	Three Years	Abstain	Broker Non-Votes
27,772,209	157,294	6,030,802	26,232	6,683,929

In light of these voting results and other factors considered by
the Board, the Board has determined that the Company will include
a stockholder vote on the compensation of the Company’s named
executive officers in its proxy materials every year until the
next required vote on the frequency of stockholder votes on the
compensation of the Company’s named executive officers or until
the Board otherwise determines that a different frequency for
such advisory votes is in the best interests of the Company’s
stockholders.

Proposal 4: Approval of the Amended and Restated Luminex
Corporation Employee Stock Purchase Plan

The stockholders approved the Amended and Restated Luminex
Corporation Employee Stock Purchase Plan, as set forth below:

Proposal 5: Ratification of Independent Auditor

The stockholders approved the ratification of the appointment by
the Company’s Audit Committee of Ernst Young LLP as the
Company’s independent registered public accounting firm for
fiscal 2017, as set forth below:

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.



Exhibit No.		Description
10.1		Amended and Restated Luminex Corporation Employee Stock Purchase Plan (Previously filed as Annex A to the Companys Proxy Statement for its Annual Meeting of Stockholders on May 18, 2017).

About LUMINEX CORPORATION (NASDAQ:LMNX)
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to various types of testing laboratories. The Company’s assay products are focused on three segments of the molecular diagnostic testing market: human genetics, personalized medicine and infectious disease. LUMINEX CORPORATION (NASDAQ:LMNX) Recent Trading Information
LUMINEX CORPORATION (NASDAQ:LMNX) closed its last trading session down -0.44 at 20.27 with 222,549 shares trading hands.